Cargando…

Efficacy and safety of high-dose esomeprazole and amoxicillin dual therapy versus bismuth-containing quadruple therapy for Helicobacter pylori infection: a multicenter, randomized controlled clinical trial

BACKGROUND: A high-dose proton pump inhibitor (PPI)-amoxicillin dual therapy has been investigated for treatment of patients with Helicobacter pylori (H. pylori) infection. Currently, the efficacy of this dual therapy remains inconclusive, with controversial findings from various single-center clini...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mei, Hao, Guo, Yan, Zhao, Jing-Tao, Yang, Jun, Sun, Wen-jing, Zhang, De-kui, He, Ping, Shi, Gang, Su, Na-yun, Han, Ran, Lan, Chun-Hui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Helicobacter pylori Infection — pathogenesis, management and prevention
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9806404/ https://www.ncbi.nlm.nih.gov/pubmed/36600686 http://dx.doi.org/10.1177/17562848221142925

Ejemplares similares

High-dose dual therapy versus bismuth-containing quadruple therapy for Helicobacter pylori eradication: a systematic review and meta-analysis with trial sequential analysis
por: Zhou, Ben-Gang, et al.
Publicado: (2023)

The efficacy and safety of Saccharomyces boulardii in addition to antofloxacin-based bismuth quadruple therapy for Helicobacter pylori eradication: a single-center, prospective randomized-control study
por: He, Xiao-Jian, et al.
Publicado: (2023)

Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan
por: Suzuki, Sho, et al.
Publicado: (2020)

Rescue therapy for refractory Helicobacter pylori infection: current status and future concepts
por: Wang, Song-Wei, et al.
Publicado: (2023)

Adequate amounts of probiotics increase the success rate of Helicobacter pylori eradication therapy in children
por: Kakiuchi, Toshihiko
Publicado: (2023)

High-dose dual therapy versus culture-based susceptibility-guided therapy as a rescue regimen for Helicobacter pylori infection: a randomized controlled trial
por: Zhao, Zhe, et al.
Publicado: (2022)

Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of Helicobacter pylori in the community and hospital populations: a randomised trial
por: Liou, Jyh-Ming, et al.
Publicado: (2016)

Dietary habits and Helicobacter pylori infection: is there an association?
por: Soares, Giovana Alice Sampaio, et al.
Publicado: (2023)

Implications of the paradigm shift in management of Helicobacter pylori infections
por: Graham, David Y.
Publicado: (2023)

Therapeutic eradication choices in Helicobacter pylori infection in children
por: Manfredi, Marco, et al.
Publicado: (2023)

Real-world outcomes associated with vonoprazan-based versus proton pump inhibitor-based therapy for Helicobacter pylori infection in Japan
por: Howden, Colin W., et al.
Publicado: (2023)

Helicobacter pylori in children: think before you kill the bug!
por: Ravikumara, M
Publicado: (2023)

Helicobacter pylori infection has a detrimental impact on the efficacy of cancer immunotherapies
por: Oster, Paul, et al.
Publicado: (2022)

Update on the second-line treatment of Helicobacter pylori infection: a narrative review
por: Shih, Chih-An, et al.
Publicado: (2023)

A pro-inflammatory role for Th22 cells in Helicobacter pylori-associated gastritis
por: Zhuang, Yuan, et al.
Publicado: (2015)

Helicobacter pylori infection and micronutrient deficiency in pregnant women: a systematic review and meta-analysis
por: Afsar, Md. Nure Alam, et al.
Publicado: (2020)

The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention
por: Lee, Yi-Chia, et al.
Publicado: (2013)

A novel human gastric primary cell culture system for modelling Helicobacter pylori infection in vitro
por: Schlaermann, Philipp, et al.
Publicado: (2016)

Pan-genomic analyses identify key Helicobacter pylori pathogenic loci modified by carcinogenic host microenvironments
por: Noto, Jennifer M, et al.
Publicado: (2018)

Update on the first-line treatment of Helicobacter pylori infection in areas with high and low clarithromycin resistances
por: Shih, Chih-An, et al.
Publicado: (2022)

Helicobacter pylori
por: Harris, A. W. (Adam W.), 1963-
Publicado: (1996)

Protein kinase C isozymes regulate matrix metalloproteinase-1 expression and cell invasion in Helicobacter pylori infection
por: Sokolova, Olga, et al.
Publicado: (2013)

CCL20/CCR6-mediated migration of regulatory T cells to the Helicobacter pylori-infected human gastric mucosa
por: Cook, Katherine W, et al.
Publicado: (2014)

Progressive genomic convergence of two Helicobacter pylori strains during mixed infection of a patient with chronic gastritis
por: Cao, Qizhi, et al.
Publicado: (2015)

USF1 defect drives p53 degradation during Helicobacter pylori infection and accelerates gastric carcinogenesis
por: Costa, Lionel, et al.
Publicado: (2020)

Efficacy of second-line regimens for Helicobacter pylori eradication treatment: a systemic review and network meta-analysis
por: Chang, Yen-Lin, et al.
Publicado: (2020)

Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study
por: Murakami, Kazunari, et al.
Publicado: (2016)

Brief communication: global temporal trends in the efficacy of clarithromycin-based regimens for the treatment of Helicobacter pylori infection
por: Moss, Steven F., et al.
Publicado: (2023)

Cost-effectiveness modelling of use of urea breath test for the management of Helicobacter pylori-related dyspepsia and peptic ulcer in the UK
por: Pritchard, D. Mark, et al.
Publicado: (2021)

Helicobacter pylori potentiates epithelial:mesenchymal transition in gastric cancer: links to soluble HB-EGF, gastrin and matrix metalloproteinase-7
por: Yin, Yinfei, et al.
Publicado: (2010)

Assessment of Helicobacter pylori status by examination of gastric mucosal patterns: diagnostic accuracy of white-light endoscopy and narrow-band imaging
por: Glover, Ben, et al.
Publicado: (2021)

Large-scale, national, family-based epidemiological study on Helicobacter pylori infection in China: the time to change practice for related disease prevention
por: Zhou, Xian-Zhu, et al.
Publicado: (2023)

Correlation of T cell response and bacterial clearance in human volunteers challenged with Helicobacter pylori revealed by randomised controlled vaccination with Ty21a-based Salmonella vaccines
por: Aebischer, T, et al.
Publicado: (2008)

Comparison of the Dual Therapy of Ilaprazole-Amoxicillin and the Bismuth Quadruple Therapy of Ilaprazole-Amoxicillin-Furazolidone-Bismuth Glycyrrhizinate for Eradication of Helicobacter pylori
por: Niu, Min, et al.
Publicado: (2022)

Non-Bismuth Quadruple Therapy, Sequential Therapy or High-Dose Esomeprazole and Amoxicillin Dual Therapy for First-Line Helicobacter pylori Eradication: A Prospective Randomized Study
por: Zeriouh, Meriem, et al.
Publicado: (2020)

Eradication efficacy of high-dose amoxicillin and proton pump inhibitor compared with quadruple therapy contained bismuth in the treatment of Helicobacter pylori
por: Hajiani, Eskandar, et al.
Publicado: (2022)

Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori
por: Gisbert, Javier P, et al.
Publicado: (2012)

Susceptibility-guided bismuth quadruple therapies for resistant Helicobacter pylori infections
por: Yang, Tiankuo, et al.
Publicado: (2020)

Dual Therapy Trial Using Esomeprazole and Amoxicillin as Third-line Rescue Therapy for Helicobacter pylori Infection
por: Park, Hyun Kyung, et al.
Publicado: (2011)

Comparison of Second-Line Quadruple Therapies with or without Bismuth for Helicobacter pylori Infection
por: Jheng, Guang-Hong, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_qfv5oclqr2snfqos22vc34pt9p